170 related articles for article (PubMed ID: 6671088)
1. Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma.
Cavo M; Baccarani M; Gobbi M; Lipizer A; Tura S
Br J Haematol; 1983 Dec; 55(4):683-90. PubMed ID: 6671088
[TBL] [Abstract][Full Text] [Related]
2. A prognostic index for multiple myeloma.
Grignani G; Gobbi PG; Formisano R; Pieresca C; Ucci G; Brugnatelli S; Riccardi A; Ascari E
Br J Cancer; 1996 May; 73(9):1101-7. PubMed ID: 8624271
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Hitz F
Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
[No Abstract] [Full Text] [Related]
4. Prognostic significance of bone marrow histology in multiple myeloma.
Subramanian R; Basu D; Dutta TK
Indian J Cancer; 2009; 46(1):40-5. PubMed ID: 19282565
[TBL] [Abstract][Full Text] [Related]
5. Early plasma cell recruitment in multiple myeloma following chemotherapy.
Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R
Cell Tissue Kinet; 1988 Nov; 21(6):405-9. PubMed ID: 3251633
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of the ratio of bone marrow plasma cells in multiple myeloma].
Pasqualetti P; Colantonio D; Casale R
Minerva Med; 1990 Mar; 81(3):129-33. PubMed ID: 2320280
[TBL] [Abstract][Full Text] [Related]
7. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.
Terpstra WE; Lokhorst HM; Blomjous F; Meuwissen OJ; Dekker AW
Br J Haematol; 1992 Sep; 82(1):46-9. PubMed ID: 1419801
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging.
Bartl R; Frisch B; Burkhardt R; Fateh-Moghadam A; Mahl G; Gierster P; Sund M; Kettner G
Br J Haematol; 1982 Jul; 51(3):361-75. PubMed ID: 7104223
[TBL] [Abstract][Full Text] [Related]
9. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of 2 prognostic classification systems for myeloma and examination of the correlation between initial bone marrow plasmacytosis and prognosis. A propos of a homogeneous population of 50 patients followed from diagnosis to death].
Pesce A; Cassuto JP; Grisot C; Gratecos N; Bayle J; Viot G; Dujardin P
Nouv Rev Fr Hematol (1978); 1983; 25(5):311-7. PubMed ID: 6657481
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma without detectable Ig synthesis.
Ferraris AM; Haupt E; Ratti M
Acta Haematol; 1979; 62(5-6):257-61. PubMed ID: 121666
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of plasma cell morphology in multiple myeloma.
Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I
Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725
[TBL] [Abstract][Full Text] [Related]
13. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.
Stifter S; Babarović E; Valković T; Seili-Bekafigo I; Stemberger C; Nacinović A; Lucin K; Jonjić N
Diagn Pathol; 2010 May; 5():30. PubMed ID: 20482792
[TBL] [Abstract][Full Text] [Related]
14. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
[No Abstract] [Full Text] [Related]
15. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in multiple myeloma.
Alexanian R; Balcerzak S; Bonnet JD; Gehan EA; Haut A; Hewlett JS; Monto RW
Cancer; 1975 Oct; 36(4):1192-201. PubMed ID: 1175123
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic and therapeutic significance of bone marrow biopsy in multiple myeloma. Analysis of 31 stage II A and III A patients].
Paule B; Quillard J; Medicis P; Bourgeois P; Grossin M; Bisson M; Kahn MF
Rev Rhum Mal Osteoartic; 1988 Jan; 55(1):27-32. PubMed ID: 3353673
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in multiple myeloma.
Cherng NC; Asal NR; Kuebler JP; Lee ET; Solanki D
Cancer; 1991 Jun; 67(12):3150-6. PubMed ID: 2044058
[TBL] [Abstract][Full Text] [Related]
19. Myeloma and related disorders.
Kyle RA; Durie BG; Boccadoro M; Pavlovsky S
Rev Invest Clin; 1994 Apr; Suppl():46-51. PubMed ID: 7886308
[No Abstract] [Full Text] [Related]
20. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
